Report adverse events:
Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com
Supporting you to support your patients with hyperkalaemia
Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com
Some of these provide more information for you and some are for you to pass onto your patients to help them understand hyperkalaemia and the medicine they have been prescribed and what else they can do to help lower their K+ levels.
Please click on the appropriate tab above to access the relevant resources.
Information on the relevance and impact of the 3 key electrolytes sodium, magnesium and calcium in the context of patients treated with Veltassa®.
Checklist with the most important elements in the treatment of chronic hyperkalemia. The material is made in collaboration with two nephrologists and two dietitians in Sweden. For more info see the attachments.
A folder with info about a sodium free option with Veltassa in hyperkalemia treatments.
A more in-depth look at how Veltassa® works.
K+, potassium; MoA, mechanism of action.
If you, as an HCP, wish to receive electronic promotional and non-promotional information from the Vifor Pharma Group, please subscribe using this form.